These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 31836855)

  • 1. Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection.
    Frigeni M; Besson C; Visco C; Fontaine H; Goldaniga M; Visentini M; Pulsoni A; Torres HA; Peveling-Oberhag J; Rossotti R; Zaja F; Rigacci L; Merli M; Dorival C; Alric C; Piazza F; Gentile M; Ferrari A; Pirisi M; Nassi L; Rattotti S; Frustaci A; Milella M; Cencini E; Defrancesco I; Ferretti VV; Bruno R; Hermine O; Arcaini L
    Leukemia; 2020 May; 34(5):1462-1466. PubMed ID: 31836855
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas.
    Kelaidi C; Rollot F; Park S; Tulliez M; Christoforov B; Calmus Y; Podevin P; Bouscary D; Sogni P; Blanche P; Dreyfus F
    Leukemia; 2004 Oct; 18(10):1711-6. PubMed ID: 15284859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From the pathogenesis to the cure of indolent B-cell lymphoproliferative disorders associated with hepatitis C virus infection: which role for direct-acting antivirals?
    Visentini M; Fiorilli M; Casato M
    Expert Rev Hematol; 2017 Aug; 10(8):719-727. PubMed ID: 28675071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between type II cryoglobulinemia and hepatitis C virus in a case treated with interferon-alpha.
    Fukumoto S; Ishimura E; Shoji S; Izumotani T; Kitahashi S; Kuroki T; Nishizawa Y; Morii H
    Nephron; 1996; 73(1):94-6. PubMed ID: 8742965
    [No Abstract]   [Full Text] [Related]  

  • 5. Successful treatment of membranoproliferative glomerulonephritis associated with hepatitis B and C virus simultaneous infection patient.
    Mima A; Iehara N; Matsubara T; Yamamoto S; Abe H; Nagai K; Matsuura M; Murakami T; Kishi S; Araoka T; Kishi F; Kondo N; Shigeta R; Yoshikawa K; Takahashi T; Kita T; Doi T; Fukatsu A
    Clin Nephrol; 2010 Feb; 73(2):167-9. PubMed ID: 20129026
    [No Abstract]   [Full Text] [Related]  

  • 6. [Long-term results of HBV and HCV infection in patients with blood system diseases].
    Garmaeva TTs; Kulikov SM; Mikhaĭlova EA; Gemdzhian EG; Gaponova TV; Grumbkova LO; Iaroslavtseva NG; Tupoleva TA; Somova AV; Makarik TA; Glinshchikova OA; Fevraleva IS; Sudarikov AB; Filatov FP; Savchenko VG
    Ter Arkh; 2011; 83(7):17-26. PubMed ID: 21894747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response.
    Malnick SD; Basevitch A
    Gastroenterology; 2006 Aug; 131(2):683; author reply 683-4. PubMed ID: 16890628
    [No Abstract]   [Full Text] [Related]  

  • 8. Persistent cryoglobulinemic vasculitis following successful treatment of hepatitis C virus.
    Levine JW; Gota C; Fessler BJ; Calabrese LH; Cooper SM
    J Rheumatol; 2005 Jun; 32(6):1164-7. PubMed ID: 15940780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bayesian models identify specific lymphoproliferative disorders associated with hepatitis C virus infection.
    Arcaini L; Pascutto C; Passamonti F; Bruno R; Merli M; Rizzi S; Orlandi E; Astori C; Rattotti S; Paulli M; Lazzarino M
    Int J Cancer; 2009 May; 124(9):2246-9. PubMed ID: 19132749
    [No Abstract]   [Full Text] [Related]  

  • 10. Is it now the time to update treatment protocols for lymphomas with new anti-virus systems?
    Luppi M; Barozzi P; Potenza L; Riva G; Morselli M; Torelli G
    Leukemia; 2004 Oct; 18(10):1572-5. PubMed ID: 15284857
    [No Abstract]   [Full Text] [Related]  

  • 11. Hepatitis C virus (HCV) infection and lymphoproliferative disorders.
    Libra M; Gasparotto D; Gloghini A; Navolanic PM; De Re V; Carbone A
    Front Biosci; 2005 Sep; 10():2460-71. PubMed ID: 15970508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin.
    Potthoff A; Berg T; Wedemeyer H;
    Scand J Gastroenterol; 2009; 44(12):1487-90. PubMed ID: 19900055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational and immunogenetic landscape of HCV-associated B-cell lymphoproliferative disorders.
    Defrancesco I; Visentini M; Zibellini S; Minafò YA; Rattotti S; Ferretti VV; Rizzo E; Varettoni M; Frigeni M; Pulsoni A; Casato M; Colantuono S; Rossi M; Candido C; Zerbi C; Bergamini F; Cristinelli C; Fabbri N; Merli M; Zuccaro V; Bruno R; Paulli M; Arcaini L
    Am J Hematol; 2021 Jun; 96(6):E210-E214. PubMed ID: 33755245
    [No Abstract]   [Full Text] [Related]  

  • 14. Lymphoproliferative disease with mixed cryoglobulinemia and hyperviscosity syndrome in an HIV-infected patient: HCV is the only culprit.
    Zanotti P; Izzo I; Casari S; Cattaneo C; Zaltron S; Spinetti A; Odolini S; Chirico C; Grecchi C; Festa E; Castelli F
    New Microbiol; 2017 Oct; 40(4):289-290. PubMed ID: 28825444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon therapy in HCV-positive mixed cryoglobulinaemia: viral and host factors contributing to efficacy of the therapy.
    Mazzaro C; Carniello GS; Colle R; Doretto P; Mazzi G; Crovatto M; Santini GF; Tulissi P; Gregoretti M; Mazzoran L; Russo A; Silvestri F; Pozzato G
    Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):343-50. PubMed ID: 9476189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naïve Patients Infected with Hepatitis C Virus Genotype 1.
    Zimmermann T; Hueppe D; Mauss S; Buggisch P; Pfeiffer-Vornkahl H; Grimm D; Galle PR; Alshuth U
    J Gastrointestin Liver Dis; 2016 Mar; 25(1):15-24. PubMed ID: 27014750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of hepatitis G virus infection on the severity of liver disease and response to interferon-alpha in patients with chronic hepatitis C.
    Martinot M; Marcellin P; Boyer N; Detmer J; Pouteau M; Castelnau C; Degott C; Aupérin A; Collins M; Kolberg J; Wilber J; Benhamou JP; Erlinger S
    Ann Intern Med; 1997 Jun; 126(11):874-81. PubMed ID: 9163288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct-acting antivirals in hepatitis C virus-positive mantle cell lymphomas.
    Merli M; Marino D; Cencini E; Rattotti S; Fraenza C; Grossi P; Bianchi B; Mora B; Sciarra R; Finotto S; Mecacci B; Passamonti F; Visco C; Arcaini L
    Hematol Oncol; 2021 Apr; 39(2):263-266. PubMed ID: 33150988
    [No Abstract]   [Full Text] [Related]  

  • 19. Successful pegylated interferon alpha2a monotherapy for hepatitis C virus infection in a transplanted patient who relapsed after the preceding course.
    Ichikawa T; Taura N; Miyaaki H; Matsuzaki M; Eguchi S; Takatsuki M; Kanematsu T; Nakao K
    Transpl Infect Dis; 2011 Aug; 13(4):438-40. PubMed ID: 21309967
    [No Abstract]   [Full Text] [Related]  

  • 20. Interferon-alpha therapy within the first year after acute hepatitis C infection in hemodialysis patients: efficacy and tolerance.
    Rocha CM; Perez RM; Narciso JL; Ferreira AP; Lemos LB; Medina-Pestana JO; Silva AE; Ferraz ML
    Eur J Gastroenterol Hepatol; 2007 Feb; 19(2):119-23. PubMed ID: 17272996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.